Stability Data Assessment
HomeServicesCMC & Quality ComplianceStability Data Assessment
Back to CMC & Quality Compliance

Stability Data Assessment

Securing Your Product's Shelf Life

Overview

Stability data is the clock ticking on your product's commercial viability. We design robust stability protocols compliant with ICH Q1 guidelines and analyze your data to support maximum shelf-life claims. We help you handle excursions, trends, and out-of-specification (OOS) results effectively.

Key Features

Protocol design (bracketing/matrixing)
Statistical analysis for shelf-life extrapolation
Temperature excursion assessment
Photostability and forced degradation studies

Our Process

1

Protocol Design

Creating efficient studies that cover all necessary conditions and timepoints.

2

Data Monitoring

Ongoing review of data to catch trends early.

3

Reporting

Authoring stability reports for annual updates and submissions.

Project Complete & Deliverables Provided

Frequently Asked Questions

For commercial batches: at least 12 months of long-term stability data at commercial scale (ICH Q1A). You can file with 6 months if you commit to continue testing and submit annual updates. For registration batches, 12 months is the minimum for most regions. We help design protocols that satisfy all regions simultaneously.

Why Choose Us

  • Maximized commercial shelf life
  • Robust support for storage conditions
  • Global climate zone compliance
  • Scientific defense of data trends

Get More Details

Request a personalized consultation and detailed information about this service.

Personalized consultation
Detailed service information
Custom timeline & proposal
Request Information

We'll respond within 24 hours

Ready to get started?

Contact our team to discuss your specific needs for Stability Data Assessment.

Schedule Consultation

What Our Clients Say

"Our stability protocol was overly complex and inefficient. Adelphi redesigned it to meet all regional requirements with 40% fewer timepoints. Smart science, better economics."

Tom Richardson

CMC Lead

Global Pharmaceutical